Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Siyata Gets Green Light from AT&T for a Slice of $100 Billion FirstNet Roll-Out

The company's pioneering technology is the first in-vehicle mobile device for FirstNet approved by AT&T. With a much-anticipated linchpin agreement with AT&T and FirstNet sealed this week, Siyata Mobile Inc. (SIM:TSX.V; SYATF:OTCQX) has catapulted itse...
Streetwise Reports | June 5, 2019 |

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...
Streetwise Reports | April 7, 2020 |

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure

Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. Gene-modified cellular and immune therapies company Enochian Biosciences Inc. (EN...
Streetwise Reports | June 9, 2020 |

New Rugged Handset Could Be A Game Changer For Siyata Mobile

First responders deserve better. Their traditional land mobile radio (LMR) setups are clunky, offer only low data speeds, and have limited coverage with dead zones that often slow down response times. Siyata Mobile Inc. ( NASDAQ: SYTA , Forum ) , with its push-to-talk ov...
Featured Submission | August 11, 2021 |

Siyata Mobile Accelerating Growth on Multiple Fronts

Expands its Global Footprint with Multiple New Contracts and a Key E-Commerce Distribution Agreement and Launches Innovative New Product Focusing on one specific niche market has long been a proven path to success. It’s also a potential road to failure if y...
Featured Submission | September 29, 2021 |

Siyata Mobile Still Bullish After Q2 Earnings Call

Earnings reports are useful for measuring financial milestones, but they don’t tell the whole story. Siyata Mobile (NASDAQ: SYTA, SYTAW) released their Q2 earnings on an October 15th call that included CEO Marc Seelenfreund, VP of Corporate Development Daniel...
Featured Submission | October 27, 2021 |

Exploration Highlights Southern British Columbia Gold-Copper Project

An exploration company focused on southern British Columbia releases its first drill results. Jiulian Resources Inc. (JLR:TSX.V) reported the results from the first two diamond drill holes at its Big Kidd property, which is located near Merritt, in southern British C...
Streetwise Reports | April 16, 2019 |

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

The key business and investment points are presented in a ROTH Capital Partners report. In a Dec. 18 research note, analyst Jonathan Aschoff reported that ROTH Capital Partners initiated coverage on Inovio Pharmaceuticals Inc. (INO:NASDAQ) with a Buy rating and a "c...
Streetwise Reports | December 27, 2019 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |
1 2 3 4 5 6 7 8 9 10 ...